VYNE Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on VYNE Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date VYNE Therapeutics Inc Strategy Report
- Understand VYNE Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
VYNE Therapeutics Inc (VYNE Therapeutics) is a clinical-stage biopharmaceutical company that develops proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory diseases. The company’s pipeline products include VYN201, VYN202 and FMX114 in the form of topical, inhalational and oral. Its VYN201 pipeline product treats nonsegmental vitiligo, rheumatological and lung diseases. The company’s VYN202 and FMX114 treat rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis (UC), crohn’s, multiple sclerosis (MS), myeloproliferative neoplastic disorders and atopic dermatitis. It develops drugs by using the InhiBET platform. VYNE Therapeutics is headquartered in Bridgewater, New Jersey, the US.
Headquarters
United States of America
Address
685 Route 202/206 N., Suite 301, Bridgewater, New Jersey, 08807
Website
vynetherapeutics.com
Telephone
1 650 4861416
No of Employees
10
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VYNE (NASD)
Revenue (2022)
$424,000
-11.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-22.6%
(2022 vs 2021)
Market Cap*
$35.3M
Net Profit Margin (2022)
XYZ
-37.9%
(2022 vs 2021)
* As of and is in US$
VYNE Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | VYNE |
| VYN201- Nonsegmental Vitiligo, Rheumatological and Lung Diseases | InhiBET |
| VYN202- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis or Crohn’s and Multiple Sclerosis, Myeloproliferative Neoplastic Disorders | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | VYNE Therapeutics Inc | Pfizer Inc | Bausch Health Companies Inc | Incyte Corp | Dermavant Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Canada | United States of America | United States of America |
| City | Bridgewater | New York | Laval | Wilmington | Long Beach |
| State/Province | New Jersey | New York | Quebec | Delaware | California |
| No. of Employees | 10 | 88,000 | 20,270 | 2,524 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Domzalski | President; Director; Chief Executive Officer | Executive Board | 2020 | 56 |
| Tyler Zeronda | Chief Financial Officer; Treasurer | Senior Management | 2021 | 37 |
| Mutya Harsch | Chief Legal Officer; General Counsel; Secretary | Senior Management | 2020 | 48 |
| Iain Stuart, Ph.D. | Chief Scientific Officer | Senior Management | 2019 | 50 |
| Steven Basta | Director | Non Executive Board | 2015 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer